5. | MCCLURE, M., Alios BioPharma, Inc., Statele Unite ale Americii, BERLIBA, E., dr., TSERTSVADZE, T., AIDS and Clinical Immunology Research Center of Georgia, Georgia, STREINU-CERCEL, A., Universitatea de Medicină şi Farmacie „Carol Davila“, România, VIJGEN, L., Janssen Research & Development BE, Beerse, Belgia, ASTRUC, B., Biotrial, Franţa, PATAT, A., Biotrial, Franţa, WESTLAND, C., Alios BioPharma, Inc., Statele Unite ale Americii, CHANDA, S., Alios BioPharma, Inc., Statele Unite ale Americii, ZHANG, Q., Alios BioPharma, Inc., Statele Unite ale Americii, KAKUDA, T., Alios BioPharma, Inc., Statele Unite ale Americii, VUONG, J., Alios BioPharma, Inc., Statele Unite ale Americii, KHORLIN, N., Alios BioPharma, Inc., Statele Unite ale Americii, BEIGELMAN, L., Alios BioPharma, Inc., Statele Unite ale Americii, BLATT, L., Alios BioPharma, Inc., Statele Unite ale Americii, FRY, J., Alios BioPharma, Inc., Statele Unite ale Americii Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects. PLoS ONE. 2018, nr. 10(13), 0-0. ISSN 1932-6203. |